Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
23 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
11 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
04 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
02 mai 2022 16h15 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
27 avr. 2022 08h25 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
13 avr. 2022 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
01 avr. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day
21 mars 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...